310 related articles for article (PubMed ID: 1834472)
1. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
2. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells.
Servis C; Lambris JD
J Immunol; 1989 Apr; 142(7):2207-12. PubMed ID: 2784456
[TBL] [Abstract][Full Text] [Related]
3. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
4. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
5. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
Kalli KR; Ahearn JM; Fearon DT
J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
7. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
8. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
10. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
[TBL] [Abstract][Full Text] [Related]
11. gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).
Frade R; Myones BL; Barel M; Krikorian L; Charriaut C; Ross GD
Eur J Immunol; 1985 Dec; 15(12):1192-7. PubMed ID: 3878789
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
14. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
15. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
[TBL] [Abstract][Full Text] [Related]
16. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.
Carel JC; Frazier B; Ley TJ; Holers VM
J Immunol; 1989 Aug; 143(3):923-30. PubMed ID: 2473114
[TBL] [Abstract][Full Text] [Related]
17. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 alpha'-chain.
Taniguchi-Sidle A; Isenman DE
J Immunol; 1994 Dec; 153(11):5285-302. PubMed ID: 7963581
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of complement C3 receptors on human astrocytes.
Gasque P; Chan P; Mauger C; Schouft MT; Singhrao S; Dierich MP; Morgan BP; Fontaine M
J Immunol; 1996 Mar; 156(6):2247-55. PubMed ID: 8690915
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes.
Barel M; Fiandino A; Delcayre AX; Lyamani F; Frade R
J Immunol; 1988 Sep; 141(5):1590-5. PubMed ID: 2842398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
